Citation
Seydoux, Emilie, et al. "Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies With Limited Somatic Mutation." Immunity, vol. 53, no. 1, 2020, pp. 98-105.e5.
Seydoux E, Homad LJ, MacCamy AJ, et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity. 2020;53(1):98-105.e5.
Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y. H., Feng, J., Whaley, R. E., Singh, S., Boeckh, M., Cohen, K. W., McElrath, M. J., Englund, J. A., Chu, H. Y., Pancera, M., McGuire, A. T., & Stamatatos, L. (2020). Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity, 53(1), 98-e5. https://doi.org/10.1016/j.immuni.2020.06.001
Seydoux E, et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies With Limited Somatic Mutation. Immunity. 2020 07 14;53(1):98-105.e5. PubMed PMID: 32561270.
TY - JOUR
T1 - Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
AU - Seydoux,Emilie,
AU - Homad,Leah J,
AU - MacCamy,Anna J,
AU - Parks,K Rachael,
AU - Hurlburt,Nicholas K,
AU - Jennewein,Madeleine F,
AU - Akins,Nicholas R,
AU - Stuart,Andrew B,
AU - Wan,Yu-Hsin,
AU - Feng,Junli,
AU - Whaley,Rachael E,
AU - Singh,Suruchi,
AU - Boeckh,Michael,
AU - Cohen,Kristen W,
AU - McElrath,M Juliana,
AU - Englund,Janet A,
AU - Chu,Helen Y,
AU - Pancera,Marie,
AU - McGuire,Andrew T,
AU - Stamatatos,Leonidas,
Y1 - 2020/06/08/
PY - 2020/05/12/received
PY - 2020/05/25/revised
PY - 2020/05/28/accepted
PY - 2020/6/21/pubmed
PY - 2020/7/24/medline
PY - 2020/6/21/entrez
KW - ACE2
KW - B cells
KW - COVID-19
KW - MERS
KW - SARS
KW - SARS-CoV-2
KW - antibodies
KW - neutralization
KW - receptor-binding domain
KW - spike protein
SP - 98
EP - 105.e5
JF - Immunity
JO - Immunity
VL - 53
IS - 1
N2 - Antibody responses develop following SARS-CoV-2 infection, but little is known about their epitope specificities, clonality, binding affinities, epitopes, and neutralizing activity. We isolated B cells specific for the SARS-CoV-2 envelope glycoprotein spike (S) from a COVID-19-infected subject 21 days after the onset of clinical disease. 45 S-specific monoclonal antibodies were generated. They had undergone minimal somatic mutation with limited clonal expansion, and three bound the receptor-binding domain (RBD). Two antibodies neutralized SARS-CoV-2. The most potent antibody bound the RBD and prevented binding to the ACE2 receptor, while the other bound outside the RBD. Thus, most anti-S antibodies that were generated in this patient during the first weeks of COVID-19 infection were non-neutralizing and target epitopes outside the RBD. Antibodies that disrupt the SARS-CoV-2 S-ACE2 interaction can potently neutralize the virus without undergoing extensive maturation. Such antibodies have potential preventive and/or therapeutic potential and can serve as templates for vaccine design.
SN - 1097-4180
UR - https://www.unboundmedicine.com/medline/citation/32561270/Analysis_of_a_SARS_CoV_2_Infected_Individual_Reveals_Development_of_Potent_Neutralizing_Antibodies_with_Limited_Somatic_Mutation_
DB - PRIME
DP - Unbound Medicine
ER -